William S. Pierce

Last updated

William S. Pierce (born January 12, 1937) is an American cardiothoracic surgeon and chemical engineer who led development of the first pneumatic heart assist pump. The Pierce-Donachy Ventricular Assist Device, also known as the Penn State Assist Pump, was designated an International Historic Mechanical Engineering Landmark by the American Society of Mechanical Engineers in 1990. [1]

Contents

Born in Wilkes-Barre, Pennsylvania, Pierce received his B.S. degree from Lehigh University in chemical engineering in 1958 and subsequently attended the University of Pennsylvania School of Medicine where he obtained an M.D. degree in 1962, together with an Alpha Omega Alpha honor. He received his surgical training at the University of Pennsylvania and at the National Heart, Lung and Blood Institute.

In 1970, Pierce was asked to join the surgical faculty at the new College of Medicine of Pennsylvania State University (Penn State Hershey Medical Center). He was appointed professor of surgery in 1977 and subsequently served as chief of the Division of Artificial Organs, chief of the Division of Cardiothoracic Surgery, director of surgical research, and associate chair of the Department of Surgery. He was awarded the Faculty Scholar Medal in 1983 and in 1986 was named Evan Pugh Professor, the university's highest academic honor.

At Penn State, Pierce established an interdisciplinary group to develop mechanical circulatory support devices and the artificial heart. The original pneumatic heart assist pump, now known as the Thoratec ventricular assist device (Thoratec Pneumatic VAD), has been used in nearly 4,000 patients for right, left, and biventricular support. His pioneering work led him to be considered around the world as a father of the ventricular assist device.

The group, including Pierce, James Donachy and its current chief, Gerson Rosenberg, went on in partnership with Arrow International of Reading, Pennsylvania, to develop the ArrowLion Heart, an implantable, permanent, left ventricular heart assist system powered by a wearable, external NiCd battery. The pump represented the first successful use of a transcutaneous energy transfer system, eliminating any transcutaneous wire, and the first clinical use of a compliance sac, eliminating the need for a transcutaneous vent. It has been used in over thirty patients to date.[ as of? ]

Pierce's artificial-organs group subsequently focused on a completely implantable electromechanical artificial heart consisting of two prosthetic blood pumps actuated by pusher plates driven by a compact DC motor. This biventricular heart pump, with its microprocessor-based digital control system, transcutaneous energy transfer system, and implanted compliance sac, has been successfully used in numerous calf implant studies.

In 2005, Pierce received the Barney Clark Award, an award for significant accomplishments in the biomedical field. [2]

Pierce received the 2007 Jacobson Innovation Award, [3] given by the American College of Surgeons to "living surgeons who have been innovators of a new development or technique in any field of surgery." He won "in recognition of his pioneering work in the conception and development of mechanical circulatory support and the total artificial mechanical heart and his contributions to surgical bioengineering and patient care." Pierce has edited three books and published more than 280 articles and 90 book chapters. He holds nine United States patents.

Publications

Some representative publications:

See also

Related Research Articles

<span class="mw-page-title-main">William DeVries</span> American physician

William Castle DeVries is an American cardiothoracic surgeon, mainly known for the first transplant of a TAH using the Jarvik-7 model.

<span class="mw-page-title-main">Artificial cardiac pacemaker</span> Medical device for artificially stimulating heart contractions

An artificial cardiac pacemaker, commonly referred to as simply a pacemaker, is an implanted medical device that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart. Each pulse causes the targeted chamber(s) to contract and pump blood, thus regulating the function of the electrical conduction system of the heart.

<span class="mw-page-title-main">Artificial heart</span> Mechanical device which replaces the heart

An artificial heart is an artificial organ device that replaces the heart. Artificial hearts are typically used to bridge the time to complete heart transplantation surgery, but research is ongoing to develop a device that could permanently replace the heart in the case that a heart transplant is unavailable or not viable. As of December 2023, there are two commercially available full artificial heart devices; in both cases, they are for temporary use, of less than a year, for total heart failure patients awaiting a human heart to be transplanted into their bodies.

AbioCor was a total artificial heart (TAH) developed by the Massachusetts-based company AbioMed. It was fully implantable within a patient, due to a combination of advances in miniaturization, biosensors, plastics and energy transfer. The AbioCor ran on a rechargeable source of power. The internal battery was charged by a transcutaneous energy transmission (TET) system, meaning that no wires or tubes penetrated the skin, reducing the risk of infection. However, because of its size, this heart was only compatible with men who had a large frame. It had a product life expectancy of 18 months.

<span class="mw-page-title-main">Cardiogenic shock</span> Shock due to heart dysfunction

Cardiogenic shock is a medical emergency resulting from inadequate blood flow to the body's organs due to the dysfunction of the heart. Signs of inadequate blood flow include low urine production, cool arms and legs, and decreased level of consciousness. People may also have a severely low blood pressure and heart rate.

<span class="mw-page-title-main">Ventricular assist device</span> Medical device to assist or replace a heart

A ventricular assist device (VAD) is an electromechanical device that provides support for cardiac pump function, which is used either to partially or to completely replace the function of a failing heart. VADs can be used in patients with acute or chronic heart failure, which can occur due to coronary artery disease, atrial fibrillation, valvular disease, and other conditions.

Gerson "Gus" Rosenberg is an American biomedical engineer. He is the Jane A. Fetter Professor of Surgery, professor of bioengineering, and chief of the Division of Applied Biomedical Engineering at Penn State's Milton S. Hershey Medical Center and Penn State College of Medicine.

Tofigh "Tofy" Mussivand was an Iranian-Canadian medical engineer of Kurdish origin who invented an artificial cardiac pump, a device that pumps blood and takes over the function of breathing during a heart surgery.

<span class="mw-page-title-main">O. H. Frazier</span> American physician

O. H. "Bud" Frazier is a heart surgeon and director of cardiovascular surgery research at the Texas Heart Institute (THI), best known for his work in mechanical circulatory support (MCS) of failing hearts using left ventricular assist devices (LVAD) and total artificial hearts (TAH).

Adrian Kantrowitz was an American cardiac surgeon whose team performed the world's second heart transplant attempt at Maimonides Medical Center in Brooklyn, New York on December 6, 1967. The infant lived for only six hours. At a press conference afterwards, Kantrowitz emphasized that he considered the operation to have been a failure.

Peer Michael Portner was a heart researcher whose work led to the development of the ventricular assist device, an electrical pump that permits patients in heart failure to survive until a heart transplant could be performed.

Destination therapy is a therapy that is final rather than being a transitional stage until another therapy—thus, in transportation metaphor, a destination in itself rather than merely a bridge or road to the destination. The term usually refers to ventricular assist devices or mechanical circulatory support to keep the existing heart going, not just until a heart transplant can occur, but for the rest of the patient's life expectancy. It is thus a course of treatment for severe heart failure patients who are not likely candidates for transplant. In contrast, bridge-to-transplant therapy is a way to stay alive long enough, and stay healthy enough, to await transplant while maintaining eligibility for transplant.

Thoratec Corporation is a United States-based company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart-failure patients worldwide. It is a global leader in mechanical circulatory support devices, particularly in ventricular assist devices (VADs).

Impella is a family of medical devices used for temporary ventricular support in patients with depressed heart function. Some versions of the device can provide left heart support during other forms of mechanical circulatory support including ECMO and Centrimag.

Charles D Fraser, Jr. is the medical director and surgeon of the Texas Center for Pediatric and Congenital Heart Disease at Dell Children's Medical Center. Formerly, Fraser was chief of congenital heart surgery and cardiac surgeon-in-charge at Texas Children's Hospital, the nation's largest pediatric hospital, served as chief of the Congenital Heart Surgery Division at Baylor College of Medicine, and director of the Adult Congenital Heart Surgery Program at the Texas Heart Institute.

William F. Bernhard was an American cardiovascular surgeon, Emeritus Professor of Surgery at Harvard Medical School, and cardiovascular surgical pioneer.

James K. Kirklin is an American cardiac surgeon who has made significant scientific and surgical contributions in the fields of heart transplantation and mechanical circulatory support devices to assist the pumping action of the heart. He was formerly Professor of Surgery (1987-2022), Director of the Division of Cardiothoracic Surgery (2006-2016), Director of the James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO) (2016–2022), and Co-Director of Comprehensive Cardiovascular Center (2011-2017) at the University of Alabama at Birmingham (UAB). While at UAB, he held the UAB Cardiovascular Research Chair (1998-2006), the John Kirklin Chair of Cardiovascular Surgery (2006-2017), and the James Kirklin Chair of Cardiothoracic Surgery (2017-2022).

Pump thrombosis (PT) is considered a specific case of a major device malfunction, and is classified as either suspected or confirmed pump thrombus. Typically, the device is an implanted blood pump such as a left ventricular assist device. The malfunction is a blockage in the flow of blood anywhere along a vessel and it is mainly due to the bio-incompatible presence of a fairly complex mechanical apparatus. Pump thrombus is dreaded complication of CF LVAD technology that can require repeat surgery to replace the pump or lead to death.

Jack Greene Copeland is an American cardiothoracic surgeon, who has established procedures in heart transplantation including repeat heart transplantation, the implantation of total artificial hearts (TAH) to bridge the time to heart transplant, innovations in left ventricular assist devices (LVAD) and the technique of "piggybacking" a second heart in a person, while leaving them the original.

Eric A. Rose is an American cardiothoracic surgeon, scientist, entrepreneur and professor and Chairman of the Department of Population Health Science & Policy, and Associate Director for Clinical Outcomes at Mount Sinai Heart. He is best known for performing the first successful paediatric heart transplant, in 1984 while at NewYork–Presbyterian Hospital (NYP).

References

  1. ↑ "Pierce-Donachy VentricularAssist Device". American Society of Mechanical Engineers . Retrieved September 19, 2024.
  2. ↑ "Dr. William Pierce Presented the 2005 Barney Clark Award". ASAIO Journal . 51 (6): xxiv–xxv. November 2005. doi:10.1097/01.mat.0000186528.78595.73. ISSN   1058-2916.
  3. ↑ "Jacobson Innovation Award Recipients". American College of Surgeons . Retrieved September 19, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.